Inj, jobevne, 10 mg
Products billed under this code include Jobevne.
Payment limit per 10 MG, by effective quarter, 3Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under Q5160
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Jobevne | Biocon Biologics Inc. | 83257-0009-11 | 10 | $821.39 |
| Jobevne | Biocon Biologics Inc. | 83257-0010-11 | 40 | $3,285.56 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $82.139 | −$0.097 | 10 MG | Inj, jobevne, 10 mg | v1, posted September 17, 2026 |
| 3Q26 | $82.236 | – | 10 MG | Inj, jobevne, 10 mg | v1, posted September 15, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026